Innate Signaling in the CNS Prevents Demyelination in a Focal EAE Model

Area of Science:

• Neuroimmunology
• Innate Immunity
• Demyelinating Diseases

Background:

• Multiple sclerosis (MS) is characterized by demyelinating lesions in the central nervous system (CNS).
• Innate immune receptor stimulation, particularly Toll-like receptor 9 (TLR9) and NOD-like receptor 2 (NOD2), has shown promise in suppressing experimental autoimmune encephalomyelitis (EAE), an MS model.
• A novel focal EAE model was developed to investigate innate signaling's impact on demyelination.

Purpose of the Study:

• To evaluate the therapeutic potential of a bispecific TLR9 and NOD2 ligand, MIS416, in a focal EAE model.
• To understand the immunomodulatory effects of intrathecal MIS416 administration on CNS pathology and immune cell infiltration.

Main Methods:

• Development of a focal EAE model by stereotactic needle insertion into the corpus callosum (CC) of EAE-immunized mice.
• Intrathecal administration of MIS416 into the cerebrospinal fluid.
• Analysis of CNS lesions, cytokine/chemokine profiles, and immune cell composition in the CNS and draining lymph nodes.

Main Results:

• Intrathecal MIS416 significantly reduced focal demyelinating lesions in the CC.
• MIS416 treatment upregulated type I and II interferons, interleukin-10, arginase-1, CCL-2, and CXCL-10 in the CNS.
• Cervical lymph nodes showed increased type II interferons and interleukin-10.
• MIS416 altered CNS infiltrates, increasing myeloid and NK cells while decreasing T cells at the lesion site.

Conclusions:

• Intrathecal administration of the TLR9/NOD2 ligand MIS416 effectively ameliorates focal demyelination in a mouse model.
• MIS416 modulates innate and adaptive immune responses within the CNS, promoting a protective environment.
• This study highlights the therapeutic potential of targeting innate immune pathways for treating demyelinating diseases like MS.